TransThera | 药捷安康 is a clinical-stage biopharmaceutical company founded in 2016, aiming to address unmet medical needs by developing innovative therapeutics through an internal research platform and open innovation. Their diverse portfolio encompasses oncology, cardiovascular, and inflammatory diseases, demonstrating a commitment to transforming therapy and innovating for global patients. Having recently secured a significant CNY260.00M in Series D investment on 20 February 2023, TransThera attracted backing from prominent investors such as Trinity Innovation Fund and Honest Capital. With a focus on biotechnology and life sciences, TransThera is poised to make a substantial impact on the healthcare industry.
TransThera | 药捷安康
Transformative Therapy! Innovation for global patients.
Founded 2016
19 employees
Series D
Total: $370.00M
Biotechnology, Life Sciences
General Information
Company Name
TransThera | 药捷安康
Founded Year
2016
Employees
19
Industries
Biotechnology, Life Sciences
Funding Stage
Series D
BounceWatch is an independent company data service, not affiliated with TransThera | 药捷安康. To contact TransThera | 药捷安康, visit transtherabio.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does TransThera | 药捷安康 compare?
A PDF of TransThera | 药捷安康 and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting TransThera | 药捷安康 soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About TransThera | 药捷安康
Business keywords: biopharmaceutical, innovation, therapeutics, oncology, cardiovascular, inflammatory diseases, clinical-stage, research platform, open innovation, global patients, unmet medical needs, transformative therapy
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series D | CNY260.00M | 2 |
|
20 Feb 2023 |
| Series D | $100.00M | 7 |
|
25 Jul 2021 |
| Series A | $10.00M | 1 |
|
13 Oct 2016 |
TransThera | 药捷安康 Alternatives & Competitors
View All Alternatives
TransThera | 药捷安康 vs
Scioto Biosciences, Inc
United States
Scioto Biosciences is a Clinical stage biotech company dedicated to innovative research and discover...
Series B
7 employees
Biotechnology, Health Care
TransThera | 药捷安康 vs
Precigen
United States
Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cel...
Post-IPO Equity
152 employees
Biotechnology, Health and Wellness
TransThera | 药捷安康 vs
Eikon Therapeutics
United States
Eikon is a late-stage clinical biopharmaceutical company dedicated to inventing and developing break...
Series D
429 employees
Biotechnology, Health Care
FAQ About TransThera | 药捷安康
Transformative Therapy! Innovation for global patients.
TransThera | 药捷安康 was founded in 2016.
TransThera | 药捷安康 operates in Biotechnology and Life Sciences. Its work centres on biopharmaceutical, innovation, therapeutics and oncology.
TransThera | 药捷安康 has approximately 19 employees.
TransThera | 药捷安康 has completed 3 funding rounds, raising a total of $370.00M. The latest funding stage is Series D.
Top alternatives and competitors to TransThera | 药捷安康 include Scioto Biosciences, Inc, Precigen, Eikon Therapeutics, Leap Therapeutics, Laminar Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TransThera | 药捷安康 and Scioto Biosciences, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for TransThera | 药捷安康, https://bouncewatch.com/company/transthera, updated 30 December 2024. When citing, please name BounceWatch and link this page.
